| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Albumin to globulin ratio, a predictor or a misleader?
|
Alkan, A.
|
|
|
26 |
2 |
p. 443-444
|
artikel
|
| 2 |
A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L
|
Hirai, F.
|
|
|
26 |
2 |
p. 363-368
|
artikel
|
| 3 |
A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials
|
Doussau, A.
|
|
|
26 |
2 |
p. 422-428
|
artikel
|
| 4 |
A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer
|
Chiappori, A.A.
|
|
|
26 |
2 |
p. 354-362
|
artikel
|
| 5 |
Assessing the benefit of bone-targeted therapies in prostate cancer, is the devil in the end point's definition?
|
Tombal, B.
|
|
|
26 |
2 |
p. 257-258
|
artikel
|
| 6 |
Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer
|
Sunakawa, Y.
|
|
|
26 |
2 |
p. 332-339
|
artikel
|
| 7 |
Can obesity be an advantage for febrile neutropenia?
|
Alkan, A.
|
|
|
26 |
2 |
p. 439-440
|
artikel
|
| 8 |
Cardiorespiratory fitness as predictor of cancer mortality: a systematic review and meta-analysis
|
Schmid, D.
|
|
|
26 |
2 |
p. 272-278
|
artikel
|
| 9 |
Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy
|
Montagna, E.
|
|
|
26 |
2 |
p. 307-313
|
artikel
|
| 10 |
Characteristics of pyrexia in BRAF V600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial
|
Menzies, A.M.
|
|
|
26 |
2 |
p. 415-421
|
artikel
|
| 11 |
Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor
|
Won, J.K.
|
|
|
26 |
2 |
p. 348-354
|
artikel
|
| 12 |
Concurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage III non-small-cell lung cancer: a review of the literature
|
Cardenal, F.
|
|
|
26 |
2 |
p. 278-288
|
artikel
|
| 13 |
Corrections to “Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features”
|
|
|
|
26 |
2 |
p. 445
|
artikel
|
| 14 |
Corrections to “Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors”
|
Soria, J.-C.
|
|
|
26 |
2 |
p. 445
|
artikel
|
| 15 |
Cyclin E amplification/overexpression is associated with poor prognosis in gastric cancer
|
Alsina, M.
|
|
|
26 |
2 |
p. 438-439
|
artikel
|
| 16 |
Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis
|
Barrera, L.
|
|
|
26 |
2 |
p. 428-435
|
artikel
|
| 17 |
Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events
|
Smith, M.R.
|
|
|
26 |
2 |
p. 368-374
|
artikel
|
| 18 |
Editorial board
|
|
|
|
26 |
2 |
p. i-ii
|
artikel
|
| 19 |
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment †
|
Whelan, J.S.
|
|
|
26 |
2 |
p. 407-414
|
artikel
|
| 20 |
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial
|
Hebbar, M.
|
|
|
26 |
2 |
p. 340-347
|
artikel
|
| 21 |
Incidence and determinants of 1-month mortality after cancer-directed surgery
|
Mahal, B.A.
|
|
|
26 |
2 |
p. 399-406
|
artikel
|
| 22 |
Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy
|
Vidal, A.D.
|
|
|
26 |
2 |
p. 374-377
|
artikel
|
| 23 |
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study
|
Bonnefoi, H.
|
|
|
26 |
2 |
p. 325-332
|
artikel
|
| 24 |
Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation
|
Madsen, C.
|
|
|
26 |
2 |
p. 393-399
|
artikel
|
| 25 |
Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma
|
Elaidi, R.
|
|
|
26 |
2 |
p. 378-385
|
artikel
|
| 26 |
Primum non nocere: do we harm stage I testicular cancer patients less by applying adjuvant chemotherapy than by failing to present this option?
|
Oldenburg, J.
|
|
|
26 |
2 |
p. 255-256
|
artikel
|
| 27 |
Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper
|
Casali, P.G.
|
|
|
26 |
2 |
p. 300-306
|
artikel
|
| 28 |
Reply to the letter to the editor ‘The harms of low-dose aspirin prophylaxis are overstated’ by P. Elwood and G. Morgan
|
Thorat, M.A.
|
|
|
26 |
2 |
p. 442-443
|
artikel
|
| 29 |
Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations †
|
Decoster, L.
|
|
|
26 |
2 |
p. 288-300
|
artikel
|
| 30 |
Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study
|
Jackisch, C.
|
|
|
26 |
2 |
p. 320-325
|
artikel
|
| 31 |
Table of Contents
|
|
|
|
26 |
2 |
p. iii-v
|
artikel
|
| 32 |
T-DM1-related telangiectasias: a potential role in secondary bleeding events
|
Sibaud, V.
|
|
|
26 |
2 |
p. 436-437
|
artikel
|
| 33 |
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
|
Salgado, R.
|
|
|
26 |
2 |
p. 259-271
|
artikel
|
| 34 |
The harms of low-dose aspirin prophylaxis are overstated
|
Elwood, P.
|
|
|
26 |
2 |
p. 441-442
|
artikel
|
| 35 |
The obesity and cancer link
|
Bifulco, M.
|
|
|
26 |
2 |
p. 440-441
|
artikel
|
| 36 |
Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center
|
Loirat, M.
|
|
|
26 |
2 |
p. 386-392
|
artikel
|
| 37 |
Withdrawal of hormone replacement therapy might affect multigene signature results in early luminal breast cancer
|
Neven, P.
|
|
|
26 |
2 |
p. 437-438
|
artikel
|
| 38 |
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
|
Gnant, M.
|
|
|
26 |
2 |
p. 313-320
|
artikel
|
Tijdschrift beschrijving